The primary reference is here #FOAMed (see comment on Figure 2) https://t.co/3prLdEmqjQ while a more recent analysis, of a very effective Rx which assumes treating in late rather than late CKD from an EU perspective can be found here https://t.co/1spypftoF
@S_brimble @poyanmehr @NephRodby Scott, found the paper . #FOAMed "A new treatment costing $2/day could be economically attractive at an HR for ESRD of 0.75 and among those in stage G3B." https://t.co/3prLdEmqjQ For a Rx costing $10/d the HR should 0.5 &
Cost:http://t.co/SBhfWImqlK (1-2$/d) Efficacy: -4.3 ml/min/1.73m2 implies a HR < 0.5 for ESRD in RCT http://t.co/AsEG5xob5q 1/2 #nephjc
Cost:http://t.co/SBhfWImqlK (1-2$/d) Efficacy: -4.3 ml/min/1.73m2 implies a HR < 0.5 for ESRD in RCT http://t.co/AsEG5xob5q 1/2 #nephjc
$ alert for pharma/nephrologists. Treatments for delaying CKD progression should be <10$/day to be cost effective http://t.co/B0jZPbPRl5
A model to project the impact of changes in GFR on quality of life and survival among persons with CKD http://t.co/14oJFhWhYw
A model to project the impact of changes in GFR on quality of life and survival among persons with CKD http://t.co/14oJFhWhYw
A model to project the impact of changes in GFR on quality of life and survival among persons with CKD http://t.co/14oJFhWhYw